Remission of refractory granulomatous primary cutaneous anaplastic large cell lymphoma to brentuximab vedotin.

Abstract

Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a rare non-Hodgkin's lymphoma that arises as a single, or multiple dome-shaped tumours on the skin. The histology is characterised by the presence of atypical lymphocytes with large irregularly shaped nuclei that express the surface marker CD30. There can be significant heterogeneity in clinical manifestation and histological pattern and in rare cases accurate diagnosis can be a challenge. Here, we present an unusual case presentation of cutaneous CD30+ anaplastic large cell lymphoma with significant granulomatous histology pattern that mimicked sarcoid. After a lack of durable response to treatments that included glucocorticoid and methotrexate, targeted treatment with anti-CD30 monoclonal antibody drug conjugate (brentuximab vedotin) yielded long-term clinical remission.

• Authors: Appalanaidu Sasapu, Andrew L J Dunn, Jerad Gardner, Henry K Wong
• Journal: BMJ case reports (BMJ Case Rep) Vol. 14 Issue 7 (Jul 21 2021) ISSN: 1757-790X [Electronic] England
• PMID: 34290015 (Publication Type: Case Reports, Journal Article)
• Copyright: © BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Chemical References

• Immunoconjugates
• Brentuximab Vedotin

Topics

• Brentuximab Vedotin
• Humans
• Immunoconjugates (therapeutic use)
• Lymphoma, Large-Cell, Anaplastic (diagnosis, drug therapy)
• Lymphoma, Primary Cutaneous Anaplastic Large Cell (drug therapy)
• Skin Neoplasms (drug therapy)